Literature DB >> 3516103

Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies.

R Patterson, P A Greenberger, J M Halwig, J L Liotta, M Roberts.   

Abstract

Eighty-four patients with allergic bronchopulmonary aspergillosis (ABPA) were evaluated for a total of 294 patient-years with a mean observation period of 3.7 years and classified by the stage of ABPA. The largest percentage of patients were in the stage IV (corticosteroid-dependent asthma stage) group. The next largest percentage were in the stage V (fibrotic, end-stage lung disease) group. Of the latter 24 patients, eight had died. In addition, we describe 13 patients with all serologic characteristics of ABPA but without central bronchiectasis. We propose that these patients have seropositive ABPA and represent the earliest cases of it that can be diagnosed in contrast with ABPA with central bronchiectasis in which lung damage is already present.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3516103     DOI: 10.1001/archinte.146.5.916

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  32 in total

Review 1.  Onset and outcome of asthma in older adults. A clinician's perspective.

Authors:  Charles E Reed
Journal:  Clin Rev Allergy Immunol       Date:  2002-02       Impact factor: 8.667

Review 2.  Allergic bronchopulmonary aspergillosis presenting as chronic cough in an elderly woman without previously documented asthma.

Authors:  Richard Roth; Michael Schatz
Journal:  Perm J       Date:  2013

Review 3.  Pathogenesis and management of aspergillosis in cystic fibrosis.

Authors:  E J Hiller
Journal:  Arch Dis Child       Date:  1990-04       Impact factor: 3.791

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations.

Authors:  Ritesh Agarwal; Sahajal Dhooria; Ashutosh Nath Aggarwal; Venkata N Maturu; Inderpaul S Sehgal; Valliappan Muthu; Kuruswamy T Prasad; Lakshmikant B Yenge; Navneet Singh; Digambar Behera; Surinder K Jindal; Dheeraj Gupta; Thanagakunam Balamugesh; Ashish Bhalla; Dhruva Chaudhry; Sunil K Chhabra; Ramesh Chokhani; Vishal Chopra; Devendra S Dadhwal; George D'Souza; Mandeep Garg; Shailendra N Gaur; Bharat Gopal; Aloke G Ghoshal; Randeep Guleria; Krishna B Gupta; Indranil Haldar; Sanjay Jain; Nirmal K Jain; Vikram K Jain; Ashok K Janmeja; Surya Kant; Surender Kashyap; Gopi C Khilnani; Jai Kishan; Raj Kumar; Parvaiz A Koul; Ashok Mahashur; Amit K Mandal; Samir Malhotra; Sabir Mohammed; Prasanta R Mohapatra; Dharmesh Patel; Rajendra Prasad; Pallab Ray; Jai K Samaria; Potsangbam Sarat Singh; Honey Sawhney; Nusrat Shafiq; Navneet Sharma; Updesh Pal S Sidhu; Rupak Singla; Jagdish C Suri; Deepak Talwar; Subhash Varma
Journal:  Lung India       Date:  2015-04

6.  Corticosteroid treatment and prognosis in pulmonary eosinophilia.

Authors:  S Capewell; B J Chapman; F Alexander; A P Greening; G K Crompton
Journal:  Thorax       Date:  1989-11       Impact factor: 9.139

Review 7.  Allergic bronchopulmonary aspergillosis.

Authors:  Richard B Moss
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

Review 8.  Asthma and Fungus: Role in Allergic Bronchopulmonary Aspergillosis (ABPA) and Other Conditions.

Authors:  Meenu Singh; Nandini Paul; Shreya Singh; Gyan Ranjan Nayak
Journal:  Indian J Pediatr       Date:  2018-03-17       Impact factor: 1.967

9.  Vanishing lung mass in a patient with asthma.

Authors:  Karan Madan; Randeep Guleria
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

10.  Antibody response to low-molecular-weight antigens of Aspergillus fumigatus in allergic bronchopulmonary aspergillosis.

Authors:  V P Kurup; P A Greenberger; J N Fink
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.